March 15 (Reuters) - Mesoblast Ltd MSB.AX
* Mesoblast says 36-month results from randomized, placebo-controlled 100- patient phase 2 trial of allogeneic mpcs in patients with chronic low back pain
* "Primary endpoint composite over 24 months was achieved by 41% of patients who received 6 million MPCS" Source text for Eikon: ID:nASXQKMHm Further company coverage: MSB.AX